115 related articles for article (PubMed ID: 35996969)
1. Truth or dare: switching BRAF/MEK inhibitors after acute interstitial nephritis in a patient with metastatic melanoma - A case report and review of the literature.
De Ryck L; Delanghe S; Jacobs C; Fadaei S; Brochez L; Saerens M
Acta Clin Belg; 2023 Jun; 78(3):215-222. PubMed ID: 35996969
[TBL] [Abstract][Full Text] [Related]
2. COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma.
van Akkooi AC; Hauschild A; Long GV; Mandala M; Kicinski M; Govaerts AS; Klauck I; Ouali M; Lorigan PC; Eggermont AM
Future Oncol; 2023 Sep; 19(30):2017-2027. PubMed ID: 37665297
[TBL] [Abstract][Full Text] [Related]
3. Granulomatous interstitial nephritis following BRAF/MEK inhibitor treatment for metastatic melanoma.
Garo F; Reboul P; Gerbal M; Moranne O
J Nephrol; 2023 Dec; 36(9):2649-2650. PubMed ID: 37578595
[No Abstract] [Full Text] [Related]
4. Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma.
Albrecht LJ; Dimitriou F; Grover P; Hassel JC; Erdmann M; Forschner A; Johnson DB; Váraljai R; Lodde G; Placke JM; Krefting F; Zaremba A; Ugurel S; Roesch A; Schulz C; Berking C; Pöttgen C; Menzies AM; Long GV; Dummer R; Livingstone E; Schadendorf D; Zimmer L
Eur J Cancer; 2024 May; 202():113976. PubMed ID: 38484692
[TBL] [Abstract][Full Text] [Related]
5. Case report: Parsonage-turner syndrome in a melanoma patient treated by BRAF/MEK inhibitors after immune checkpoint inhibitors.
Bonnefin C; Duval F; Rouanet M; Kostine M; Gerard E
Front Oncol; 2023; 13():1268693. PubMed ID: 38192629
[TBL] [Abstract][Full Text] [Related]
6. Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib.
Chapman PB; Klang M; Postow MA; Shoushtari AN; Sullivan RJ; Wolchok JD; Merghoub T; Budhu S; Wong P; Callahan MK; Zheng B; Zippin J
Cancer Res Commun; 2023 Dec; 3(12):2447-2454. PubMed ID: 37930123
[TBL] [Abstract][Full Text] [Related]
7. Bilateral Spontaneous Supraspinatus Tendon Rupture Under Prolonged BRAF/MEK Targeting Treatment in a Melanoma Patient.
Bafaloukos D; Gazouli I; Koutserimpas C; Skarlos PD; Samonis G
Cureus; 2023 Dec; 15(12):e50567. PubMed ID: 38222175
[TBL] [Abstract][Full Text] [Related]
8. Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E-mutated lung adenocarcinoma.
Ota T; Okabayashi A; Fukuoka M
Respirol Case Rep; 2021 Oct; 9(10):e0841. PubMed ID: 34484797
[TBL] [Abstract][Full Text] [Related]
9. Successful Treatment with Dabrafenib/Trametinib of a Malignantly Transformed and Metastasized BRAF V600E Mutant Pleiomorphic Xanthoastrocytoma: A Case Report and Review of the Literature.
Vermeulen E; Vander Mijnsbrugge AS; Brock S; Vaeyens F; Dirven I; Ciçek A; Marcelis W; Klein S; Bruneau M; Neyns B; Duerinck J
Case Rep Oncol; 2024; 17(1):10-16. PubMed ID: 38179547
[TBL] [Abstract][Full Text] [Related]
10. A case of melanoma complicated with uveitis induced by two types of BRAF/MEK inhibitors and nivolumab treatment.
Obaru C; Kimura T; Yamamura M; Kuriyama H; Kashiwada-Nakamura K; Mizuhashi S; Matsumura T; Watanabe T; Inoue T; Fukushima S
J Dermatol; 2024 Apr; 51(4):e115-e117. PubMed ID: 37927219
[No Abstract] [Full Text] [Related]
11. Regorafenib in patients with pretreated advanced melanoma: a single-center case series.
Vander Mijnsbrugge AS; Cerckel J; Dirven I; Tijtgat J; Vounckx M; Claes N; Neyns B
Melanoma Res; 2024 May; ():. PubMed ID: 38801446
[TBL] [Abstract][Full Text] [Related]
12. Durable Complete Response of a Recurrent Mesencephalic Glioblastoma Treated with Trametinib and Low-Dose Dabrafenib in a Patient with Neurofibromatosis Type 1.
Awada G; Serruys D; Schwarze JK; Van De Voorde L; Duerinck J; Neyns B
Case Rep Oncol; 2020; 13(2):1031-1036. PubMed ID: 33082744
[TBL] [Abstract][Full Text] [Related]
13. Rapid diurnal variation of serous retinal detachment during BRAF and MEK inhibitor treatment: A case series.
Bravetti GE; Muggler K; Ben Aissa A; Thumann G; Malclès A
Acta Ophthalmol; 2024 Jun; 102(4):e651-e656. PubMed ID: 38235944
[No Abstract] [Full Text] [Related]
14. BRAF
Finke C; Mohr P
Adv Ther; 2024 May; ():. PubMed ID: 38806993
[TBL] [Abstract][Full Text] [Related]
15. Real-world efficacy and safety of BRAF-targeted therapy for patients with advanced melanoma: A single-center retrospective study in Japan.
Nakano E; Takahashi A; Ogata D; Namikawa K; Yamazaki N
J Dermatol; 2024 May; ():. PubMed ID: 38716655
[TBL] [Abstract][Full Text] [Related]
16. MAP2K1 K57N Conferred an Acquired Resistance to Furmonertinib, Dabrafenib and Trametinib Combined Therapy in Advanced Lung Adenocarcinoma with EGFR Mutation and BRAF V600E.
Tan X; Wu Z; Chen M
Onco Targets Ther; 2024; 17():307-312. PubMed ID: 38617091
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib-induced acute kidney injury via interstitial nephritis.
Markóth C; File I; Szász R; Bidiga L; Balla J; Mátyus J
Ren Fail; 2021 Dec; 43(1):335-339. PubMed ID: 33567947
[TBL] [Abstract][Full Text] [Related]
18. Case report: A case of metastatic BRAFV600-mutated melanoma with heart failure treated with immune checkpoint inhibitors and BRAF/MEK inhibitors.
Nishizawa A; Kawakami M; Kitahara Y
Front Oncol; 2024; 14():1366532. PubMed ID: 38529375
[TBL] [Abstract][Full Text] [Related]
19. Acute and chronic kidney function decline in patients receiving BRAF/MEK inhibitors for melanoma.
Mistry K; Zhao S; Strohbehn I; Wang Q; Hanna P; Strohbehn S; Katz-Agranov N; Sullivan RJ; Sise ME
Nephrol Dial Transplant; 2024 May; 39(6):1040-1043. PubMed ID: 38389257
[No Abstract] [Full Text] [Related]
20. Targeted therapy in melanoma - the role of BRAF, RAS and KIT mutations.
Goldinger SM; Murer C; Stieger P; Dummer R
EJC Suppl; 2013 Sep; 11(2):92-6. PubMed ID: 26217117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
